VAXCYTE, INC. (PCVX)
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Preferred Bank Announces Quarterly Dividend
TomaGold Announces Results of its Annual Meeting
TomaGold annonce les résultats de son assemblée annuelle
Kuehn Law Encourages Investors of SelectQuote, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Charter Communications, Inc. to Contact Law Firm
Walker & Dunlop Arranges $350 Million Facility for Centerbridge Partners and Reframe Holdings to Build Institutional Self-Storage Platform
Kuehn Law Encourages Investors of CTO Realty Growth, Inc. to Contact Law Firm
Daytona RideNow Dealerships Defy Trends with Record-Breaking Sales at Daytona Bike Week 2026
Kuehn Law Encourages Investors of Ardent Health, Inc. to Contact Law Firm